Oragenics, Inc. Announces Approval To Initiate Phase II Concussion Drug Trial in Australia
UF Innovate | Accelerate graduate Oragenics announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase II clinical trial evaluating ONP-002 for the treatment of mild traumatic brain injury (mTBI).
